About Cleerly
Cleerly Health improves the diagnosis and treatment of heart disease using artificial intelligence to analyze coronary computed tomography angiography (CCTA) imaging. This technology helps clinicians detect atherosclerosis earlier and provides detailed insights into plaque types, allowing for personalized treatment plans. Unlike traditional methods, Cleerly's platform offers a more comprehensive evaluation of cardiovascular health. The goal is to enhance patient outcomes and financial results for healthcare providers through actionable clinical insights.
New York City, New YorkHeadquarters
2017Year Founded
$406.4MTotal Funding
SERIES_CCompany Stage
AI & Machine Learning, HealthcareIndustries
51-200Employees
Benefits
Medical, dental, and vision plans
Stock Options
401(k) matching program
Company wide holidays
Self-managed PTO
Risks
Increased competition from AI-driven cardiovascular imaging companies threatens market share.
Reliance on FDA approvals poses risks if future devices face delays.
Rapid AI advancements require Cleerly to continuously innovate to stay competitive.
Differentiation
Cleerly integrates AI with clinical science for coronary artery disease insights.
Their platform transforms complex imaging data into actionable insights for clinicians.
Cleerly's AI analyzes CCTA imaging to identify atherosclerosis at early stages.
Upsides
Cleerly raised $106M to scale growth and clinical evidence generation.
FDA Breakthrough Device Designation boosts Cleerly's credibility and market potential.
New AMA CPT code enhances reimbursement prospects for Cleerly's ISCHEMIA software.
Funding
Total raised$406.39 M
Latest valuation$1.11 B
StageSERIES_C
SERIES B
5/31/2021$43
$215.00 MSERIES A
3/31/2020$14
$72.40 M